Prime Medicine, Inc.

Prime Medicine is the Prime Editing gene-therapy franchise for rare diseases (AATD, epilepsy, others). Down 7% today at 20% of the 52-week range after winning the Beam Therapeutics arbitration ruling, this is a coiling turnaround setup with real catalyst-cleared upside.

• The reported mechanics are pre-revenue biotech: Q1 revenue was $856K with -117% gross margin and -5,118% operating margin — this is a pipeline-value story, not an earnings business.
• The Beam arbitration win is the transformational catalyst: Prime won a binding favorable arbitration ruling versus Beam Therapeutics over the 2019 Collaboration and License Agreement — PM647 (AATD editing therapy) is now cleared for clinical advancement and Prime doesn't owe Beam any money.
• The sell-side stack is unusually broad and bullish: BofA at $47 PT (Buy), Oppenheimer $11, Wedbush $8, Citizens $7, LifeSci $6 — real coverage width supporting the compounder-in-transition read.
• The ARPA-H and Liu Lab catalysts are the medium-term tailwinds: $34.5M ARPA-H award for gene editing in rare pediatric epilepsy plus a Liu Lab Nature Nanotechnology paper reporting ~49% precise indel-free prime editing in mouse liver — real technology-platform validation.

The path if it works is the Aug 6 Q2 print with a firm PM647 clinical timeline confirmed, a specific cash-runway commentary (Q1 burn ~$43M), and an ARPA-H program update — that turns coiling into a real move toward the BofA $47 target range. Continued deep operating losses without pipeline progress, another dilutive raise, or a Beam appeal is what keeps this at $3.52.